当前位置: X-MOL首页全球导师 国内导师 › 周红刚

个人简介

学科方向:分子药理学 招生方向:药理学,细胞生物学,分子生物学 2010毕业于英国雷丁大学(University of Reading, UK)药学院药理系,获博士学位;2011年入职南开大学药学院,2015年晋升为副教授。现任南开大学药学院院长助理、实验仪器平台主任和成果转化中心主任。主要研究方向为通过对新结构合成化合物、中药单体及衍生物、新蛋白抗体和临床药物在分子、细胞和动物水平上进行筛选;开发器官炎症/纤维化和肿瘤等适应症的创新药物,并研究其分子药理机制。主持“国自然面上基金”1项、青年项目1项、主持“天津市科技重大专项”1项;作为骨干参与“国家重大专项”2项,天津市科技重大专项与工程1项;主持承担企业横向课题15项(纵向和横向课题合计到账金额为1500余万元)。指导大学生创新创业大赛,共获国家/天津市/校级奖共计30次,其中获国家铜奖2次,天津市各奖项12次,2020年获“南开大学创新创业优秀指导教师”称号。作为主要研究者进行了多个化药1类新药临床前研究,获批新药临床批件2件(南开大学首个临床批件证书)。目前已向国家药品监督管理局申请CP0119项目新药临床批件(化药1类,肠道慢传输动力)。入选了天津市“用三年时间引进千名以上高层次人才”和“滨海新区天津市131创新型第二层次”人才称号。担任“天津市药理学会呼吸与危重症医学专业委员会”第一届委员。连续四年指导研究生获得国家奖学金,2021年获“南开大学优秀硕士学位论文指导教师”称号。共申报发明专利92项,获得授权30项;共发表文章105篇,其中以第一作者或通讯作者发表文章58篇,其中一类高质量论文15篇,累计影响因子为285.7,h-index为22。 【在研课题】(有硕士名额,欢迎同学们咨询) 抗肺纤维化药物研发及特发性肺纤维化致病机制研究 1. 创新生物药在新冠肺炎引起的肺纤维化后遗症中的作用研究(军事医学科学院联合合作项目) 2. 2019新冠病毒肺炎临床药物(瑞德西韦、阿比朵尔等)和中药单体对细胞因子风暴和治疗后肺纤维化的作用研究(天津市科技局“新型冠状病毒感染应急防治”科技重大专项) 3. 针对特发性肺纤维化 1类新药CP0116的机制机理与临床前研究(国家十三五重大新药创制科技重大专项“治疗特发性肺纤维化创新药物的研发”) 4. 靶向特发性肺纤维化中和性抗体药物研发 5. 多靶点酪氨酸激酶抑制剂TRI在肺纤维化中作用机制研究 6. “上市药物再开发”治疗肺纤维化作用药效和机制研究 7. PAR1抑制剂Vorapaxar抗纤维化作用及药理机制研究 8. 特发性肺纤维化潜在创新靶点作用机制研究 9. FOXO3相关非编码RNA在IPF中作用机制研究及抗肺纤维化小核酸药物研发 10. 天然植物提取物FKA抗纤维化作用及药理机制研究 器官纤维化筛选评价体系构建及活性先导化合物成药性评价 1. 器官纤维化筛选评价体系构建及活性先导化合物成药性评价(天津市科技计划项目“肺纤维化药物研发平台建设”) 2. 特发性肺纤维化 1类新药CP0116抗器官纤维化适应症拓展研究 3. 皮肤纤维化类瘢痕增生疾病药物筛选体系建立及治疗药物研发 4. FGFR抑制剂在心脏纤维化中药效及药理作用研究 5. 阿昔替尼缓解肝纤维化作用机制研究 呼吸系统、免疫炎症和代谢相关疾病评价体系构建及活性先导化合物成药性评价 1. 结缔组织疾病相关间质性肺疾病药物筛选体系建立及先导化合物成药性评价 2. 急性肺损伤筛选评价体系构建及活性先导化合物成药性评价 3. 免疫炎症疾病高通量细胞筛选评价体系构建及活性先导化合物成药性评价 4. 治疗慢传输型便秘的化药I类新药CP0119临床前研究(华润医药联合开发) 5. 银屑病动物模型建立及优势化合物筛选 6. 尼达尼布在炎性肠病中作用机制研究 7. 消化系统疾病动物模型完善与药物筛选 8. 代谢类疾病动物模型完善与药物筛选 靶向抗肿瘤药物开发及抗肿瘤药理机制研究 1. 杨梅素靶向PAR1逆转肿瘤细胞上皮-内皮转变抑制血管拟态形成的分子机制研究 2. 肺癌合并肺纤维化动物模型建模方法研究及药物筛选与药效评价 3. 治疗腹水癌的药物筛选及药效评价 4. FKA靶向CXCL12/CXCR4通路抑制肿瘤侵袭转移及血管生成拟态形成的分子机制研究 5. 靶向STAT3的抗肿瘤药物筛选及药理机制研究 6. 靶向PAR2的抗肿瘤增敏剂筛选及肿瘤增敏作用研究 7. PAR1-STAT3转录复合体在肿瘤恶性演进中的分子机制研究 【指导本科生/研究生创新创业比赛获奖情况】 1.“Msherb中药口红”项目,获国家级铜奖1次、市级三等奖1次、校级银奖1次。 2.“金菊罗甘”项目,获国家级铜奖1次、市级金奖1次、市级优秀奖1次、校级三等奖1次。 3. 术绍“芪”黄项目,获市级金奖1次、校级优秀奖1次。 4. 齐心“核”力助力山东省泰安市徂徕山乡村振兴项目,获市级银奖1次,校级优秀奖1次。 5.“雾灵景天清新精华液”项目,获市级二等奖1次、校级金奖1次,校级优秀奖1次。 6.“长生不老的药-Araceae新药开拓”项目,获市级优秀奖1次、市级三等奖1次、校级二等奖1次。 7.“瑞格菲尼和帕唑帕尼在肺纤维化治疗中的应用”项目,获市级二等奖3次、校级一等奖1次、校级二等奖2次、校级三等奖2次。 8.“格列齐特在肺纤维化治疗中的应用”项目,获校级三等奖2次、优秀奖1次。 9. “抗特发性肺纤维化药物筛选及作用机制研究-以靶向VEGFR、FGFR、PDGF上市抗肿瘤药物为例”项目,获校级一等奖1次。 10. “果蔬农残清洗剂”项目,获校级一等奖1次。 11. “瑞戈非尼水合物在制备治疗肺纤维化疾病药物中的应用”项目,获校级三等奖2次。

研究领域

1. 肺纤维化创新靶点机制研究及基于临床需求的创新药物研发 2. 皮肤纤维化(瘢痕疙瘩)筛选评价体系构建及活性先导化合物成药性评价 3. 心脏纤维化等器官纤维化创新疾病机制研究及药物筛选体系建立和药物评价 4. 结缔组织疾病相关间质性肺疾病等呼吸系统疾病机制研究及创新药物研发 5. 免疫炎症和代谢类疾病评价体系构建及活性先导化合物成药性评价 6. 靶向抗肿瘤药物开发及抗肿瘤药理机制研究 7. 治疗肺癌合并肺纤维化疾病的药物筛选与药效评价 8. 创新药物和中药/天然药物复杂成分的体内外药物代谢与药物动力学研究

近期论文

查看导师最新文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

1. Ming Wang, Shanfa Ren, Zhun Bi, Liang Zhang, Mengqi Cui, Ronghao Sun, Jiali Bao, Dandi Gao, Bo Yang, Xiaoping Li, Mingjiang Li, Ting Xiao*, Honggang Zhou*, Cheng Yang. Myricetin reverses epithelial–endothelial transition and inhibits vasculogenic mimicry and angiogenesis of hepatocellular carcinoma by directly targeting PAR1. Phytotherapy Research, 2022. 2. Xiaohe Li, Yinshan Fang, Dingyuan Jiang, Yingying Dong, Yingying Liu, Si Zhang, Jiasen Guo, Chao Qi, Chenjing Zhao, Fangxin Jiang, Yueyue Jin, Jing Geng, Cheng Yang, Hongkai Zhang, Bin Wei, Jiurong Liang, Chen Wang, Huaping Dai, Honggang Zhou*, Dianhua Jiang*, and Wen Ning*. Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases. Molecular Therapy, 2021. 3. Xiaohe Li†, Ling Ma†, Kai Huang†, Yuli Wei, Shida Long, Qinyi Liu, Deqiang Zhang, Shuyang Wu, Wenrui Wang, Guang Yang*, Honggang Zhou* and Cheng Yang*. Regorafenib-Attenuated Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-β1 Signaling Pathway. International Journal of Molecular Sciences, 2021. 4. Xiaohe Li†, Yanhua Wang†, Jingjing Liang†, Zhun Bi†, Hao Ruan†, Yunyao Cui, Ling Ma, Yuli Wei, Bingchen Zhou, Liang Zhang, Honggang Zhou*, Cheng Yang*. Bergenin attenuates bleomycin-induced pulmonary fibrosis in mice via inhibiting TGF-β1 signaling pathway. Phytotherapy Research, 2021. 5. Xiaohe Li†, Rui Liu†, Yunyao Cui†, Jingjing Liang†, Zhun Bi†, Shimeng Li, Yang Miao, Liang Zhang, Xiaoping Li, Honggang Zhou* and Cheng Yang. Protective Effect of Remdesivir Against Pulmonary Fibrosis in Mice. Frontiers in Pharmacology, 2021. 6. Xiaohe Li†, Kai Huang†, Xiaowei Liu†, Hao Ruan†, Ling Ma, Jingjing Liang, Yunyao Cui, Yanhua Wang, Shuyang Wu, Hailong Li, Yuli Wei, Zeping Li, Jingjing Gao, Bo Yang, Xiaoping Li, Guang Yang*, Honggang Zhou* and Cheng Yang*. Ellagic Acid Attenuates BLM-Induced Pulmonary Fibrosis via Inhibiting Wnt Signaling Pathway. Frontiers in Pharmacology, 2021. 7. Hailong Li, Rui Liu, Ruotong Zhang, Shanshan Zhang, Yiying Wei, Liang Zhang, Honggang Zhou* and Cheng Yang*. Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice. Frontiers in Pharmacology, 2021. 8. Ting Xiao , Mengqi Cui, Caijuan Zheng, Ming Wang, Ronghao Sun, Dandi Gao, Jiali Bao, Shanfa Ren, Bo Yang, Jianping Lin, Xiaoping Li, Dongmei Li*, Cheng Yang* and Honggang Zhou*. Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting Mpro and Ameliorates Pulmonary Inflammation. Frontiers in Pharmacology,2021. 9. Xiaohe Li, § Xiaowei Liu, § Ruxia Deng, § Shaoyan Gao, § Qiuyan Jiang, Rui Liu, Hailong Li, Yang Miao, Yunqian Zhai, Shanshan Zhang, Zhenzhen Wang, Yimeng Ren, Wen Ning, Honggang Zhou*, Cheng Yang,*. Betulinic acid Attenuated Bleomycin-induced Pulmonary Fibrosis by Effectively Intervening Wnt/β-catenin Signaling. Phytomedicine, 2021. 10. Xiaohe Li, Ling Ma, Yuli Wei, Jinying Gu, Jingjing Liang, Shimeng Li, Yunyao Cui, Rui Liu, Hui Huang, Cheng Yang, Honggang Zhou*. Cabozantinib ameliorates lipopolysaccharide-induced lung inflammation and bleomycin--induced early pulmonary fibrosis in mice. International Immunopharmacology,2021. 11. Shuangling Li, Shaoyan Gao, Qiuyan Jiang, Qing Liang, Jiaoyan Luan, Ruiqin Zhang, Fangxia Zhang, Hao Ruan, Xiaohe Li, Xiaoping Li, Honggang Zhou*, Cheng Yang. Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization. International Immunopharmacology,2021. 12. Xiaohe Li, Qing Liang, Shaoyan Gao, Qiuyan Jiang, Fangxia Zhang, Ruiqin Zhang, Hao Ruan, Shuangling Li, Jiaoyan Luan, Ruxia Deng, Honggang Zhou*, Hui Huang*, Cheng Yang*. Lenalidomide attenuates post-inflammation pulmonary fibrosis through blocking NF-κB signaling pathway. International Immunopharmacology,2021. 13. Xiaohe Li, Hailong Li, Shanshan Zhang, Ruotong Zhang, Jinhe Li, Yiying Wei, Cheng Yang, Fubo Zhang*, Honggang Zhou*. Protective effect of Idelalisib on carbon tetrachloride-induced liver fibrosis via microRNA-124-3P/phosphatidylinositol-3-hydr oxykinase signalling pathway. Journal of Cellular and Molecular Medicine,2021. 14. Xiaohe Li†, Yunqian Zhai†, Buri Xi†, Wei Ma†, Jianwei Zhang, Xiaoyang Ma, Yang Miao, Yongjian Zhao, Wen Ning,*, Honggang Zhou,* and Cheng Yang. Pinocembrin Ameliorates Skin Fibrosis via Inhibiting TGF‐β1 Signaling Pathway. Biomolecules,2021. 15. Heng Zhang, Zhi Chang, Lu-ning Qin, Bin Liang, Jing-xia Han, Kai-liang Qiao, Cheng Yang, Yan-rong Liu*, Honggang Zhou* and Tao Sun*. MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells, Signal Transduction and Targeted Therapy, 2021. 16. Hai-long Li, Yi-ying Wei, Xiao-he Li, Shan-shan Zhang, Ruo-tong Zhang, Jin-he Li, Bo-wei Ma, Shuai-bo Shao, Zi-wei Lv, Hao Ruan, Honggang Zhou* and Cheng Yang. Diosmetin has therapeutic efficacy in colitis regulating gut microbiota, inflammation, and oxidative stress via the circ-Sirt1/Sirt1 axis. Acta Pharmacologica Sinica,2021. 17. Ting Xiao, Yuli Wei, Mengqi Cui, Xiaohe Li, Hao Ruan, Liang Zhang, Jiali Bao, Shanfa Ren, Dandi Gao, Ming Wang, Ronghao Sun, Mingjiang Li, Dongmei Li*, Cheng Yang*, Honggang Zhou*. Effect of dihydromyricetin on SARS-CoV-2 viral replication and pulmonary inflammation and fibrosis, Phytomedicine, 2021. 18. Wenhua Gan, § Xiaohe Li, § Yunyao Cui, § Ting Xiao, Rui Liu, Ming Wang, Yiying Wei, Mengqi Cui, Shanfa Ren, Kaiyue Helian, Wen Ning, Honggang Zhou*, Cheng Yang*. Pinocembrin relieves lipopolysaccharide and bleomycin induced lung inflammation via inhibiting TLR4-NF-κB-NLRP3 inflammasome signaling pathway. International Immunopharmacology, 2021. 19. Xiaohe Li, Buri Xi, Yang Miao, Xiaoyang Ma, Jianwei Zhang, Jingjing Gao, Wenguo Wei*, Honggang Zhou*, Cheng Yang. Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF-κB and VEGFR2 signaling. International Immunopharmacology,2021. 20. Hao Ruan† , Jiaoyan Luan†, Shaoyan Gao†, Shuangling Li, Qiuyan Jiang, Rui Liu, Qing Liang, Ruiqin Zhang, Fangxia Zhang, Xiaohe Li, Honggang Zhou* and Cheng Yang. Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway. Molecules,2021. 21. Hao Ruan, Shaoyan Gao, Shuangling Li, Jiaoyan Luan, Qiuyan Jiang, Xiaohe Li, Huijun Yin*, Honggang Zhou* and Cheng Yang*. Deglycosylated Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1 Signaling Pathway. Molecules,2021. 22. Ting Xiao, Mengqi Cui, Caijuan Zheng, Peipei Zhang, Shanfa Ren, Jiali Bao, Dandi Gao, Ronghao Sun, Ming Wang, Jianping Lin, Liang Zhang, Mingjiang Li, Dongmei Li*, Honggang Zhou* and Cheng Yang*. Both Baicalein and Gallocatechin Gallate Effectively Inhibit SARS‐CoV‐2 Replication by Targeting Mpro and Sepsis in Mice, Inflammation, 2021. 23. Ruotong Zhang, Yiying Wei, Shanshan Zhang, Hailong Li, Jinhe Li, Bowei Ma, Xiaoqing Zhu, Xudong Song*, Honggang Zhou*. Inhibitory effect of Idelalisib on selenite-induced cataract in Sprague Dawley rat pups. Current Eye Research,2021. 24. 张杉杉,李海龙,李晓平,李霄鹤*,周红刚*. 酪氨酸激酶抑制剂与器官纤维化研究进展. 中国药学杂志,2022. 25. 崔梦奇,任善发,王 明,高丹迪,肖 婷*,周红刚*,杨 诚*. PARs在IPF中的作用及其靶向药物研究进展. 生命科学,2021. 26. 姜秋燕,梁 庆,高劭妍,李霄鹤,黄 慧,周红刚*. 特发性肺纤维化治疗药物研究进展. 中国新药杂志,2021. 27. 邓如霞,张瑞芹,高劭妍,黄慧,李霄鹤,周红刚*. 尼达尼布抗器官纤维化研究进展. 中国药学杂志,2021. 28. 苗洋,李霄鹤,翟芸芊,白佳坤,马晓阳,希布日,张建伟,周红刚*,杨诚*. 特发性肺纤维化抗体药物研发进展. 药学学报,2021. 29. 卫怡颖,李诗檬,魏文国,周红刚*. 银屑病治疗药物的研究进展. 中国当代医药,2021.

学术兼职

担任”Journal of Cellular and Molecular Medicine”、“International Journal of Immunopathology and Pharmacology ”、“Artificial Cells Nanomedicine and Biotechnology”等18个期刊审稿人

推荐链接
down
wechat
bug